Interius BioTherapeutics’ US$76 Million Series A financing.

Sidley Austin LLP advised Interius BioTherapeutics on the deal.

Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, announced its US$76 million Series A financing.

The round was co-led by Cormorant Asset Management and Fairmount Funds, and joined by Bain Capital Life Sciences, Pfizer Ventures, RA Capital Management, Longwood Fund, Logos Capital, Osage University Partners, and Quan Capital. All existing investors participated, including lead founding investor Tellus BioVentures, the University of Pennsylvania and Penn Medicine, Agent Capital, the Mark Foundation for Cancer Research, Knollwood, and BrightEdge, the American Cancer Society’s impact investment fund. Tomas Kiselak of Fairmount Funds and Ben Lund of Bain Capital Life Sciences will join the Interius Board of Directors.

The Sidley team was led by Asher Rubin (Picture) and Alison Lehner, and included Anna Razzaio and Zachary Shub-Essig.

Involved fees earner: Alison Lehner – Sidley Austin LLP; Anna Razzaio – Sidley Austin LLP; Asher Rubin – Sidley Austin LLP; Zachary Shub-Essig – Sidley Austin LLP;

Law Firms: Sidley Austin LLP;

Clients: Interius BioTherapeutics;

Author: Martina Bellini